Clarification on PharmAGRI’s Alleged Purchase of Optimus Robots
Elon Musk recently addressed the reports circulating about PharmAGRI, a US pharmaceutical and agricultural infrastructure company, planning to deploy 10,000 Optimus robots for its operations. Musk took to the social media platform X to provide clarity on the situation.
The initial reports suggested that PharmAGRI Capital Partners had signed a Letter of Intent with Tesla to utilize up to 10,000 Optimus Gen 3+ humanoid robots in its SuperPharm and CEA facilities. The purpose behind this deployment was to automate labor processes and enhance security measures.
Lynn Stockwell, Chairwoman & CEO of PharmAGRI, had previously stated that the company was indeed partnering with Tesla for this initiative. She mentioned that by incorporating Tesla robotics into their facilities, along with DEA-licensed infrastructure, they aimed to achieve precision, compliance with federal regulations, and the production of secure, American-made therapies.
Elon Musk’s Response
Following the widespread coverage of PharmAGRI’s purported purchase of Optimus robots, some Tesla enthusiasts expressed skepticism. They questioned the feasibility of Tesla committing such a large number of robots to a relatively unknown company at this stage. Additionally, the authenticity of PharmAGRI’s claims was brought into question, with some pointing out the simplistic nature of their website and images of Tesla Optimus bots.
In response to these discussions, Elon Musk directly addressed the situation by simply stating, “Fake.” This reaction was not unexpected, considering that the development of Optimus robots is still ongoing, making it unlikely for Tesla to be engaging in customer orders or Letters of Intent at this early stage. Musk emphasized that Tesla’s current focus remains on perfecting the upcoming Optimus V3, which he has described as “sublime.”